MedWatch

Novo-CSO: It’s a setback, we have to admit it

It is a setback – but no catstrophe – for Novo Nordisk that Tresiba failed to win approval in the US, the company’s CSO says. He points out that a pre-approval study will be less extensive and expensive than a post-approval study.

Foto: Novo Nordisk/PR

It is a major setback for Novo Nordisk in the battle for control of the market for long-acting insulin that Tresiba is not set to hit the US market for some time to come now, Novo’s Chief Science Officer, Mads Krogsgaard Thomsen, admits to Medwatch.

“It is a strain for us as far as basal insulin is concerned, we have to admit. Tresiba is approved in Japan, Europe and Mexico, but not on the single largest market in the world – the US market. We are not in the lead there, Sanofi is with Lantus, and Tresiba was set to usurp that pole position. But it is not right around the next bend anymore and we are obviously annoyed and disappointed about it,” he says.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier